Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (5): 583-589.doi: 10.12092/j.issn.1009-2501.2024.05.014

Previous Articles     Next Articles

Research progress on CXC chemokines and their receptors and pulmonary fibrosis

CHEN Feng1, LI Long2, WANG Jie1, LIU Shengfei 1   

  1. 1First Clinical School of Lanzhou University, Lanzhou 730000, Gansu, China; 2Department of Respiratory and Critical Care Medicine, First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2023-09-20 Revised:2023-11-27 Online:2024-05-26 Published:2024-04-16

Abstract:

Pulmonary fibrosis (PF) is a common, persistent, irreversible, fatal chronic lung disease with a median survival of 2-4 years after diagnosis. It is characterized by excessive extracellular matrix deposition and scarring in the lungs, leading to functional failure, severe respiratory problems and even death. Numerous studies have shown that CXC chemokines and their receptors play important roles in PF and other desmoplastic disorders. Several studies have shown that chemokines may become new targets for the treatment of many diseases. Here, we review the role of key CXC chemokines and their receptors in PF to provide a reference for the treatment of PF.

Key words: pulmonary fibrosis, CXC chemokine, CXC chemokine receptor

CLC Number: